Orthomolecular Solutions to Heart Disease Real threat to the medical industry

[Guest guest]

http://www.newmediaexplorer.org/chris/2003/06/03/orthomolecular_solutions_to_heart_disease.htm

 

 

Orthomolecular Solutions to Heart DiseaseControl tactics

Practical Health

 

The following simple solution to prevent heart disease is currently

ignored in favour of paradigm of more invasive and lucrative disease

management. Studying the the data below, one could conclude that the

eradication of the this disease has been known for some time but is

simply being ignored. This is an update to a note I sent to a number of

people who wanted to know about some inexpensive non drug solutions.

This note is by no means complete as I have not covered herbal and

other mineral adjuncts. So far - 5 people. that I know, have tired

vitamin C and Lysine and have had very good results.

 

Chris Gupta

 

This type of empowered and cost effective disease prevention is

becoming a real threat to the medical industry thus the CODEX

initiative. Again, at the risk of boring the reader, I direct you to

the following link and encourage you to educate as many people as

possible on this imminent loss of safe health solutions and our

freedoms. http://www.iahf.com/anh_lawsuit.html

 

1) Linus Pauling Therapy for Heart Disease is at http://www.paulingtherapy.com/

and copiously describes a non toxic, cost effective Orthomolecular

approach using vitamin C and amino acids Lysine and Proline.

 

16] According to the Pauling/Rath 1994 United States patent, the amino

acid lysine (lysine analogs), along with vitamin C and other

antioxidants (e.g. Co-Q10, vitamin E and vitamin A), can, in sufficient

concentration, inhibit Lp(a) binding to exposed lysine residues.

Proline residues are also exposed by lesions in blood vessels. Later

experiments showed that proline as well as lysine, with vitamin C,

other amino acids and antioxidants, in oral amounts well past what is

needed for prevention, becomes a solvent by inhibiting the binding of

Lp(a). A binding inhibitor augmented with vitamin C can stop and

apparently even reverses some plaque formations. Pauling and Rath even

have a second U. S. patent for using these binding inhibitors as

solvents to melt atherosclerotic plaques from human organs during organ

transplants. The organ is dipped in the Lp(a) Binding Inhibitor

solution and the plaques melt away.

 

U. S. Patent # 5,278,189 is for the prevention and treatment of

occlusive cardiovascular disease with vitamin C and substances that

inhibit the binding of lipoprotein-(a).

 

See also patent 5,230,996 .

 

 

Backing this up with Vitamin B6 is described in the Joe Hattersley

paper "Vitamin B6: The overlooked Key to preventing heart attacks" More

supporting data in response to my earlier email also has been included

at the end of this note

 

ABSTRACT: Vitamin B6 (pyridoxine) opens the door to eliminating the

20th century's epidemic of heart attacks, cardiac arrests and strokes.

Although shunned by the researchers who receive the bulk of heart

disease research funding, it is creating excitement among a growing

number of investigators. In this article relevant bits of B6's history

are presented to show how it can prevent heart attacks with almost no

side effects from moderate amounts. This article will also integrate

the effects of vitamin B6 deficiency with Mathias Rath and Linus

Pauling's theory (blaming heart attacks on deficient vitamin C and

excess Lp(a) and Bruce Lipton's histamine theory into a general theory

of atherogenesis.

 

Vitamin B6 The overlooked Key to preventing heart attacks.PDF

 

As usual any effective products such as amino acids (mentioned below)

which are very effective for many diseases and essentially non toxic

(far less toxic than even salt) are banned illegally by Health Canada

to protect their pharmaceutical friends! So you will have get them from

the states - 250 (500 mg) tablets of lysine are available for approx $5

from US Walmart stores. The underground cost in Canada is over $50

courtesy of Health Canada.

 

 

Chris Gupta

 

See also:

 

Reduction of Lipoprotein(a) in Postmenopausal Women

 

As a general surgeon who is interested in the prevention of

postmenopausal heart disease and in particular in the reduction of

lipoprotein(a) [Lp(a)], I read with great interest the recent review by

Dr Mosca1 regarding the role of HRT. Rapid progression of

arteriographically determined coronary artery disease has been

significantly more common in subjects with Lp(a) levels higher than 25

mg/dL.2 Approximately 33% of the population have elevated levels of

Lp(a) (>25 mg/dL), a condition that is an independent risk factor

for coronary artery disease.3, 4 The treatment currently recommended

for postmenopausal women with Lp(a) levels higher than 25 mg/dL

consists of a combination of HRT and niacin.4 The adverse effects of

niacin use are flushing, headache, and liver dysfunction. I am a

53-year-old woman with a significantly elevated level of Lp(a) (27

mg/dL), but I found that I had to stop taking niacin primarily because

of headaches. Thus, after a thorough review of the literature, I

began to follow the advice of Linus Pauling. For individuals who have

an Lp(a) level higher than 25 mg/dL and a family history of heart

disease, the recommendation is to take 3 g/d of both ascorbic acid and

L-lysine monohydrochloride.5 After 6 months of this regimen, with no

adverse effects, my Lp(a) level decreased to 14 mg/dL, a reduction of

48%. The Lp(a) testing was done by the highly reliable Lawrence

Berkeley National Laboratory/Berkeley HeartLab Department Technology

Transfer program. The theory is that lysine is an Lp(a)-binding

inhibitor and thus blocks the Lp(a) attachment to the arterial blood

vessel wall and that ascorbic acid helps to repair the collagen injury

to the blood vessel and acts as an antioxidant.5-7 Currently, pilot

studies are being conducted on the Pauling therapy of elevated levels

of Lp(a).

 

Kathie M. Dalessandri, MS, MD

Point Reyes Station, Calif

 

 

1. Mosca L. The role of hormone replacement therapy in the prevention

of postmenopausal heart disease. Arch Intern Med. 2000;60:2263-2272.

 

2. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid

angiographic progression of coronary artery disease in patients with

elevated lipoprotein(a). Circulation. 1995;91:948-950. MEDLINE

 

3. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma

lipoprotein(a) and coronary heart disease in men aged 55 years and

younger: a prospective study. JAMA. 1996;276:544-548. MEDLINE

 

4. Superko HR. Did grandma give you heart disease? the new battle

against coronary artery disease. Am J Cardiol. 1998;82:34Q-46Q. MEDLINE

 

 

5. Pauling L, Rath M. Solution to the puzzle of human cardiovascular

disease: its primary cause is ascorbate deficiency leading to the

deposition of lipoprotein(a) and fibrinogen/fibrin in the vascular

wall. J Orthomol Med. 1992;6:125-133.

 

6. Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for

ascorbate. Proc Natl Acad Sci U S A. 1990;87:6204-6207. MEDLINE

 

7. Pauling L. The Last Interview [videotape]. Lisle, Ill: Intellisoft

Multimedia Inc; 1994.

 

(Arch Intern Med. March 12, 2001;161:772-773,)

 

Reduction of Lipoprotein(a) in Postmenopausal Women

http://archinte.ama-assn.org/issues/v161n5/ffull/ilt0312-4.html

 

 

In response to the above Joe wrote

JosephHattersley

Fri, 30 May 2003 13:18:52 EDT

Re: Orthomolecular Solutions to Heart Disease

 

Good work, Chris. On vitamin B6 why not add the info from trials:

 

(1) Thousands of people in East Texas took 50-300 milligrams of B6

daily for many years under the guidance of John Marion Ellis, MD, of

Mt. Pleasant, Texas. He urged no change in the lives of patients

suffering from carpal tunnel syndrome and osteoarthritis -- those

symptoms accurately portray high cardiac risk -- except "Take vitamin

B6." Yet a retrospective study found his patients had 73 percent fewer

chest pains and heart attacks than thousands of ab-stainers in the same

area; they lived seven to 17 years longer; and they felt better. Ellis

JM, McCully KS. Prevention of myocardial infarction by vitamin B6.

Research Comm Molec Path and Pharmacol 1995; 89; 2:208-220.

 

(They -- and patients of Moses M. Suzman, MD, using B6 from 1950-1990

-- never complained of over publicized neurological side effects. A few

people may be sensitive to this vitamin as pyridoxine hydrochloride,

its common supplemented form. Russell Jaffe, MD, PhD, eliminated

neurological side effects among thousands of volunteers by using

pharmaceutical grade B6, 200 to 2,000 milligrams daily for up to two

years. Lecture in Seattle, 1990. The product is available from VRP

1-800-877-2447; 1-702-884-1300 www.vrp.com, and possibly from others.)

 

(2) Among a sample of women followed for 20 years in the prospective

Nurses' Health Study, after adjustment for other risk factors heart

attack risk dropped 17 percent for each two-milligram increase in daily

B6 consumption in both diet and supplements. Higher intakes yielded

lower cardiac risk; an increase of eight milligrams might then lower

risk by 68%. Rimm EB, Willett WC et al. Folate and vitamin B6 from diet

and supplements in relation to risk of coronary heart disease among

women. Journal American Medical Assoc. 1998; 279; 5:359-364.

 

(3) In the 10-year ARIC (Atherosclerosis Risk in Communities) study,

the people in the highest quintile of plasma vitamin B6 had 72 percent

fewer heart attacks than those in the lowest quintile of plasma B6. As

in Dr. Ellis's experience, for non-cardiac patients nothing but B6 made

any difference in cardiac risk - not even now-famous homocysteine.

Folsom AR, Nieto FJ et al. Prospective study of coronary heart disease

incidence in relation to fasting total homo-cysteine, related genetic

polymorphisms, and B vitamins. Circulation 1998; 98:204-210.

 

Moses M. Suzman, MD, of Johannesburg, South Africa, earlier confirmed

that finding with tens of thousands of patients over a period of forty

years but did not publish the results. Hattersley JG. Acquired

atherosclerosis: Theories of causation, novel therapies. Jour

Orthomolecular Med 1991; 6:83-98. Derived from 50 telephone

conversations and a 3-day stay at Dr. Suzman's home in Johannesburg,

April 1992, with several interviews.

 

The findings appear to confirm all the requirements for proof that

vitamin B6 prevents heart attacks. Doll, Sir Richard. Proof of

causality. Deduction from epidemiological observation. Perspectives

Biol Med 2002; 45; 4: 499-515

..

Cordially, Joe

 

See also: Bad News About Statin Drugs